Follow The Filings

SRTS Sensus Healthcare

Sensus Healthcare earnings company data as of 12:01 PM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -0.53 —
Rev — $2.3M —

Insider trades

Open-market buys and sales by SRTS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SRTS insider trades
  • $728K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Eric Sachetta Director
    Buy
    $226K 64,841 shares at $3.48 +28% to stake
    Traded Aug 28–31 Filed Aug 31
  2. Eric Sachetta Director
    Buy
    $67K 20,633 shares at $3.23 +9.9% to stake
    Traded Aug 26–27 Filed Aug 28
  3. Eric Sachetta Director
    Buy
    $113K 34,697 shares at $3.25 +20% to stake
    Traded Aug 24 Filed Aug 25
  4. Eric Sachetta Director
    Buy
    $98K 31,000 shares at $3.16 +22% to stake
    Traded Aug 20–21 Filed Aug 24
  5. Joseph C Sardano CEO
    Buy
    $60K 20,000 shares at $3.02 +1.7% to stake
    Traded Aug 20 Filed Aug 24
  6. Eric Sachetta Director
    Buy
    $5,003 1,500 shares at $3.34 +1.1% to stake
    Traded May 12 Filed May 12
  7. Eric Sachetta Director
    Buy
    $7,620 2,000 shares at $3.81 +1.4% to stake
    Traded Feb 24 Filed Feb 26
  8. Eric Sachetta Director
    Buy
    $28K 7,000 shares at $3.93 +5.3% to stake
    Traded Nov 21, 2025 Filed Nov 21, 2025
  9. Eric Sachetta Director
    Buy
    $11K 2,500 shares at $4.50 +1.9% to stake
    Traded Nov 13, 2025 Filed Nov 20, 2025
  10. Michael Sardano President and General Counsel
    Buy
    $3,800 1,000 shares at $3.80 +0.8% to stake
    Traded Nov 18, 2025 Filed Nov 19, 2025
  11. Joseph C Sardano CEO
    Buy
    $101K 25,000 shares at $4.03 +2.1% to stake
    Traded Nov 18, 2025 Filed Nov 19, 2025
  12. Michael Sardano President and General Counsel
    Buy
    $8,546 2,000 shares at $4.27
    Traded Nov 11, 2025 Filed Nov 18, 2025

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
8-K 1.01,9.01
8-K 5.07
10-Q
8-K 2.02,9.01
DEF 14A
10-K
8-K 2.02,9.01
8-K 4.01,9.01
8-K 5.02,9.01
8-K 5.02,9.01
10-Q
8-K 2.02,9.01
10-Q
8-K 2.02,9.01
8-K 5.07
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.